nodes	percent_of_prediction	percent_of_DWPC	metapath
Nifedipine—ABCC3—Vincristine—lymphatic system cancer	0.126	0.168	CbGbCtD
Nifedipine—ABCC3—Methotrexate—lymphatic system cancer	0.0763	0.102	CbGbCtD
Nifedipine—CYP1A2—Carmustine—lymphatic system cancer	0.066	0.088	CbGbCtD
Nifedipine—CYP3A5—Teniposide—lymphatic system cancer	0.0596	0.0795	CbGbCtD
Nifedipine—ABCC2—Vincristine—lymphatic system cancer	0.0573	0.0764	CbGbCtD
Nifedipine—CYP2E1—Mitoxantrone—lymphatic system cancer	0.0537	0.0715	CbGbCtD
Nifedipine—CYP2C9—Teniposide—lymphatic system cancer	0.04	0.0533	CbGbCtD
Nifedipine—CYP3A7—Vincristine—lymphatic system cancer	0.0383	0.051	CbGbCtD
Nifedipine—CYP3A7-CYP3A51P—Vincristine—lymphatic system cancer	0.0383	0.051	CbGbCtD
Nifedipine—ABCC2—Methotrexate—lymphatic system cancer	0.0347	0.0462	CbGbCtD
Nifedipine—CYP3A5—Vincristine—lymphatic system cancer	0.0287	0.0382	CbGbCtD
Nifedipine—ABCB1—Mitoxantrone—lymphatic system cancer	0.0271	0.0362	CbGbCtD
Nifedipine—CYP3A4—Cytarabine—lymphatic system cancer	0.0236	0.0315	CbGbCtD
Nifedipine—CYP3A4—Teniposide—lymphatic system cancer	0.0233	0.031	CbGbCtD
Nifedipine—ABCB1—Vincristine—lymphatic system cancer	0.0187	0.0249	CbGbCtD
Nifedipine—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0163	0.0217	CbGbCtD
Nifedipine—ABCB1—Methotrexate—lymphatic system cancer	0.0113	0.0151	CbGbCtD
Nifedipine—CYP3A4—Vincristine—lymphatic system cancer	0.0112	0.0149	CbGbCtD
Nifedipine—Coma—Methotrexate—lymphatic system cancer	0.000388	0.00155	CcSEcCtD
Nifedipine—Back pain—Carmustine—lymphatic system cancer	0.000387	0.00155	CcSEcCtD
Nifedipine—Discomfort—Bleomycin—lymphatic system cancer	0.000386	0.00155	CcSEcCtD
Nifedipine—Mental disorder—Vincristine—lymphatic system cancer	0.000385	0.00154	CcSEcCtD
Nifedipine—Chills—Mitoxantrone—lymphatic system cancer	0.000384	0.00154	CcSEcCtD
Nifedipine—Urine output increased—Methotrexate—lymphatic system cancer	0.000383	0.00154	CcSEcCtD
Nifedipine—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.000382	0.00153	CcSEcCtD
Nifedipine—Gynaecomastia—Methotrexate—lymphatic system cancer	0.000379	0.00152	CcSEcCtD
Nifedipine—Alopecia—Mitoxantrone—lymphatic system cancer	0.000378	0.00151	CcSEcCtD
Nifedipine—Pulmonary oedema—Methotrexate—lymphatic system cancer	0.000378	0.00151	CcSEcCtD
Nifedipine—Confusional state—Bleomycin—lymphatic system cancer	0.000377	0.00151	CcSEcCtD
Nifedipine—Vision blurred—Carmustine—lymphatic system cancer	0.000377	0.00151	CcSEcCtD
Nifedipine—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000376	0.00151	CcSEcCtD
Nifedipine—Tremor—Carmustine—lymphatic system cancer	0.000375	0.0015	CcSEcCtD
Nifedipine—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000374	0.0015	CcSEcCtD
Nifedipine—Oedema—Bleomycin—lymphatic system cancer	0.000374	0.0015	CcSEcCtD
Nifedipine—Erythema—Mitoxantrone—lymphatic system cancer	0.000372	0.00149	CcSEcCtD
Nifedipine—Anaemia—Carmustine—lymphatic system cancer	0.00037	0.00148	CcSEcCtD
Nifedipine—Back pain—Vincristine—lymphatic system cancer	0.00037	0.00148	CcSEcCtD
Nifedipine—Vomiting—Teniposide—lymphatic system cancer	0.000369	0.00148	CcSEcCtD
Nifedipine—Agitation—Carmustine—lymphatic system cancer	0.000368	0.00147	CcSEcCtD
Nifedipine—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000366	0.00147	CcSEcCtD
Nifedipine—Asthenia—Fludarabine—lymphatic system cancer	0.000366	0.00147	CcSEcCtD
Nifedipine—Rash—Teniposide—lymphatic system cancer	0.000366	0.00147	CcSEcCtD
Nifedipine—Dermatitis—Teniposide—lymphatic system cancer	0.000366	0.00147	CcSEcCtD
Nifedipine—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000364	0.00146	CcSEcCtD
Nifedipine—Headache—Teniposide—lymphatic system cancer	0.000364	0.00146	CcSEcCtD
Nifedipine—Pruritus—Fludarabine—lymphatic system cancer	0.000361	0.00145	CcSEcCtD
Nifedipine—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.000361	0.00145	CcSEcCtD
Nifedipine—Back pain—Mitoxantrone—lymphatic system cancer	0.00036	0.00144	CcSEcCtD
Nifedipine—Leukopenia—Carmustine—lymphatic system cancer	0.000358	0.00144	CcSEcCtD
Nifedipine—Anorexia—Bleomycin—lymphatic system cancer	0.000357	0.00143	CcSEcCtD
Nifedipine—Anaemia—Vincristine—lymphatic system cancer	0.000353	0.00141	CcSEcCtD
Nifedipine—Agitation—Vincristine—lymphatic system cancer	0.000351	0.00141	CcSEcCtD
Nifedipine—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000351	0.0014	CcSEcCtD
Nifedipine—Polyuria—Methotrexate—lymphatic system cancer	0.000351	0.0014	CcSEcCtD
Nifedipine—Hypotension—Bleomycin—lymphatic system cancer	0.00035	0.0014	CcSEcCtD
Nifedipine—Diarrhoea—Fludarabine—lymphatic system cancer	0.000349	0.0014	CcSEcCtD
Nifedipine—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000345	0.00138	CcSEcCtD
Nifedipine—Nausea—Teniposide—lymphatic system cancer	0.000345	0.00138	CcSEcCtD
Nifedipine—Anaemia—Mitoxantrone—lymphatic system cancer	0.000344	0.00138	CcSEcCtD
Nifedipine—Vertigo—Vincristine—lymphatic system cancer	0.000343	0.00138	CcSEcCtD
Nifedipine—Leukopenia—Vincristine—lymphatic system cancer	0.000342	0.00137	CcSEcCtD
Nifedipine—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000341	0.00137	CcSEcCtD
Nifedipine—Chest pain—Carmustine—lymphatic system cancer	0.000341	0.00137	CcSEcCtD
Nifedipine—Myalgia—Carmustine—lymphatic system cancer	0.000341	0.00137	CcSEcCtD
Nifedipine—Anxiety—Carmustine—lymphatic system cancer	0.00034	0.00136	CcSEcCtD
Nifedipine—Paraesthesia—Bleomycin—lymphatic system cancer	0.000336	0.00135	CcSEcCtD
Nifedipine—Malaise—Mitoxantrone—lymphatic system cancer	0.000336	0.00134	CcSEcCtD
Nifedipine—Dyspnoea—Bleomycin—lymphatic system cancer	0.000334	0.00134	CcSEcCtD
Nifedipine—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000333	0.00133	CcSEcCtD
Nifedipine—Confusional state—Carmustine—lymphatic system cancer	0.000329	0.00132	CcSEcCtD
Nifedipine—Oedema—Carmustine—lymphatic system cancer	0.000327	0.00131	CcSEcCtD
Nifedipine—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.000326	0.00131	CcSEcCtD
Nifedipine—Decreased appetite—Bleomycin—lymphatic system cancer	0.000325	0.0013	CcSEcCtD
Nifedipine—Myalgia—Vincristine—lymphatic system cancer	0.000325	0.0013	CcSEcCtD
Nifedipine—Visual disturbance—Methotrexate—lymphatic system cancer	0.000325	0.0013	CcSEcCtD
Nifedipine—Cough—Mitoxantrone—lymphatic system cancer	0.000325	0.0013	CcSEcCtD
Nifedipine—Vomiting—Fludarabine—lymphatic system cancer	0.000325	0.0013	CcSEcCtD
Nifedipine—Rash—Fludarabine—lymphatic system cancer	0.000322	0.00129	CcSEcCtD
Nifedipine—Dermatitis—Fludarabine—lymphatic system cancer	0.000322	0.00129	CcSEcCtD
Nifedipine—Pain—Bleomycin—lymphatic system cancer	0.00032	0.00128	CcSEcCtD
Nifedipine—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00032	0.00128	CcSEcCtD
Nifedipine—Headache—Fludarabine—lymphatic system cancer	0.00032	0.00128	CcSEcCtD
Nifedipine—Tachycardia—Carmustine—lymphatic system cancer	0.000319	0.00128	CcSEcCtD
Nifedipine—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.000318	0.00127	CcSEcCtD
Nifedipine—Myalgia—Mitoxantrone—lymphatic system cancer	0.000317	0.00127	CcSEcCtD
Nifedipine—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000317	0.00127	CcSEcCtD
Nifedipine—Chest pain—Mitoxantrone—lymphatic system cancer	0.000317	0.00127	CcSEcCtD
Nifedipine—Anxiety—Mitoxantrone—lymphatic system cancer	0.000316	0.00126	CcSEcCtD
Nifedipine—Discomfort—Mitoxantrone—lymphatic system cancer	0.000313	0.00125	CcSEcCtD
Nifedipine—Oedema—Vincristine—lymphatic system cancer	0.000312	0.00125	CcSEcCtD
Nifedipine—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000312	0.00125	CcSEcCtD
Nifedipine—Anorexia—Carmustine—lymphatic system cancer	0.000311	0.00125	CcSEcCtD
Nifedipine—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000308	0.00124	CcSEcCtD
Nifedipine—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000308	0.00123	CcSEcCtD
Nifedipine—Confusional state—Mitoxantrone—lymphatic system cancer	0.000306	0.00123	CcSEcCtD
Nifedipine—Nervous system disorder—Vincristine—lymphatic system cancer	0.000306	0.00123	CcSEcCtD
Nifedipine—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000305	0.00122	CcSEcCtD
Nifedipine—Hypotension—Carmustine—lymphatic system cancer	0.000305	0.00122	CcSEcCtD
Nifedipine—Oedema—Mitoxantrone—lymphatic system cancer	0.000304	0.00122	CcSEcCtD
Nifedipine—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000304	0.00122	CcSEcCtD
Nifedipine—Nausea—Fludarabine—lymphatic system cancer	0.000303	0.00121	CcSEcCtD
Nifedipine—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000301	0.00121	CcSEcCtD
Nifedipine—Shock—Mitoxantrone—lymphatic system cancer	0.000299	0.0012	CcSEcCtD
Nifedipine—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000298	0.00119	CcSEcCtD
Nifedipine—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000297	0.00119	CcSEcCtD
Nifedipine—Urticaria—Bleomycin—lymphatic system cancer	0.000297	0.00119	CcSEcCtD
Nifedipine—Anorexia—Vincristine—lymphatic system cancer	0.000297	0.00119	CcSEcCtD
Nifedipine—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000296	0.00119	CcSEcCtD
Nifedipine—Body temperature increased—Bleomycin—lymphatic system cancer	0.000296	0.00119	CcSEcCtD
Nifedipine—Insomnia—Carmustine—lymphatic system cancer	0.000295	0.00118	CcSEcCtD
Nifedipine—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000295	0.00118	CcSEcCtD
Nifedipine—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000294	0.00118	CcSEcCtD
Nifedipine—Paraesthesia—Carmustine—lymphatic system cancer	0.000293	0.00118	CcSEcCtD
Nifedipine—Mood swings—Methotrexate—lymphatic system cancer	0.000292	0.00117	CcSEcCtD
Nifedipine—Hypotension—Vincristine—lymphatic system cancer	0.000291	0.00117	CcSEcCtD
Nifedipine—Dyspnoea—Carmustine—lymphatic system cancer	0.000291	0.00117	CcSEcCtD
Nifedipine—Somnolence—Carmustine—lymphatic system cancer	0.00029	0.00116	CcSEcCtD
Nifedipine—Anorexia—Mitoxantrone—lymphatic system cancer	0.00029	0.00116	CcSEcCtD
Nifedipine—Ataxia—Methotrexate—lymphatic system cancer	0.000289	0.00116	CcSEcCtD
Nifedipine—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000284	0.00114	CcSEcCtD
Nifedipine—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000284	0.00114	CcSEcCtD
Nifedipine—Decreased appetite—Carmustine—lymphatic system cancer	0.000284	0.00114	CcSEcCtD
Nifedipine—Hypotension—Mitoxantrone—lymphatic system cancer	0.000284	0.00114	CcSEcCtD
Nifedipine—Insomnia—Vincristine—lymphatic system cancer	0.000282	0.00113	CcSEcCtD
Nifedipine—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000282	0.00113	CcSEcCtD
Nifedipine—Paraesthesia—Vincristine—lymphatic system cancer	0.00028	0.00112	CcSEcCtD
Nifedipine—Pain—Carmustine—lymphatic system cancer	0.000279	0.00112	CcSEcCtD
Nifedipine—Constipation—Carmustine—lymphatic system cancer	0.000279	0.00112	CcSEcCtD
Nifedipine—Breast disorder—Methotrexate—lymphatic system cancer	0.000278	0.00111	CcSEcCtD
Nifedipine—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.000277	0.00111	CcSEcCtD
Nifedipine—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000277	0.00111	CcSEcCtD
Nifedipine—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000276	0.0011	CcSEcCtD
Nifedipine—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000273	0.00109	CcSEcCtD
Nifedipine—Decreased appetite—Vincristine—lymphatic system cancer	0.000271	0.00109	CcSEcCtD
Nifedipine—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000271	0.00108	CcSEcCtD
Nifedipine—Somnolence—Mitoxantrone—lymphatic system cancer	0.00027	0.00108	CcSEcCtD
Nifedipine—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000269	0.00108	CcSEcCtD
Nifedipine—Feeling abnormal—Carmustine—lymphatic system cancer	0.000269	0.00108	CcSEcCtD
Nifedipine—Fatigue—Vincristine—lymphatic system cancer	0.000269	0.00108	CcSEcCtD
Nifedipine—Asthenia—Bleomycin—lymphatic system cancer	0.000269	0.00108	CcSEcCtD
Nifedipine—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000267	0.00107	CcSEcCtD
Nifedipine—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000267	0.00107	CcSEcCtD
Nifedipine—Constipation—Vincristine—lymphatic system cancer	0.000267	0.00107	CcSEcCtD
Nifedipine—Pain—Vincristine—lymphatic system cancer	0.000267	0.00107	CcSEcCtD
Nifedipine—Pruritus—Bleomycin—lymphatic system cancer	0.000265	0.00106	CcSEcCtD
Nifedipine—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000264	0.00106	CcSEcCtD
Nifedipine—Eosinophilia—Methotrexate—lymphatic system cancer	0.000263	0.00106	CcSEcCtD
Nifedipine—Fatigue—Mitoxantrone—lymphatic system cancer	0.000262	0.00105	CcSEcCtD
Nifedipine—Constipation—Mitoxantrone—lymphatic system cancer	0.00026	0.00104	CcSEcCtD
Nifedipine—Pain—Mitoxantrone—lymphatic system cancer	0.00026	0.00104	CcSEcCtD
Nifedipine—Abdominal pain—Carmustine—lymphatic system cancer	0.000258	0.00103	CcSEcCtD
Nifedipine—Body temperature increased—Carmustine—lymphatic system cancer	0.000258	0.00103	CcSEcCtD
Nifedipine—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.000255	0.00102	CcSEcCtD
Nifedipine—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000255	0.00102	CcSEcCtD
Nifedipine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00025	0.001	CcSEcCtD
Nifedipine—Dysuria—Methotrexate—lymphatic system cancer	0.000249	0.000997	CcSEcCtD
Nifedipine—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000248	0.000995	CcSEcCtD
Nifedipine—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000247	0.000991	CcSEcCtD
Nifedipine—Abdominal pain—Vincristine—lymphatic system cancer	0.000247	0.000988	CcSEcCtD
Nifedipine—Body temperature increased—Vincristine—lymphatic system cancer	0.000247	0.000988	CcSEcCtD
Nifedipine—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000245	0.000982	CcSEcCtD
Nifedipine—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000243	0.000973	CcSEcCtD
Nifedipine—Urticaria—Mitoxantrone—lymphatic system cancer	0.000241	0.000966	CcSEcCtD
Nifedipine—Hypersensitivity—Carmustine—lymphatic system cancer	0.000241	0.000964	CcSEcCtD
Nifedipine—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00024	0.000962	CcSEcCtD
Nifedipine—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00024	0.000962	CcSEcCtD
Nifedipine—Vomiting—Bleomycin—lymphatic system cancer	0.000238	0.000953	CcSEcCtD
Nifedipine—Rash—Bleomycin—lymphatic system cancer	0.000236	0.000945	CcSEcCtD
Nifedipine—Dermatitis—Bleomycin—lymphatic system cancer	0.000236	0.000944	CcSEcCtD
Nifedipine—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000235	0.000942	CcSEcCtD
Nifedipine—Asthenia—Carmustine—lymphatic system cancer	0.000234	0.000939	CcSEcCtD
Nifedipine—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000231	0.000924	CcSEcCtD
Nifedipine—Hypersensitivity—Vincristine—lymphatic system cancer	0.00023	0.00092	CcSEcCtD
Nifedipine—Sweating—Methotrexate—lymphatic system cancer	0.000227	0.000911	CcSEcCtD
Nifedipine—Haematuria—Methotrexate—lymphatic system cancer	0.000226	0.000906	CcSEcCtD
Nifedipine—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000224	0.000899	CcSEcCtD
Nifedipine—Epistaxis—Methotrexate—lymphatic system cancer	0.000224	0.000896	CcSEcCtD
Nifedipine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000224	0.000896	CcSEcCtD
Nifedipine—Asthenia—Vincristine—lymphatic system cancer	0.000224	0.000896	CcSEcCtD
Nifedipine—Diarrhoea—Carmustine—lymphatic system cancer	0.000224	0.000895	CcSEcCtD
Nifedipine—Nausea—Bleomycin—lymphatic system cancer	0.000222	0.000891	CcSEcCtD
Nifedipine—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000221	0.000887	CcSEcCtD
Nifedipine—Asthenia—Mitoxantrone—lymphatic system cancer	0.000218	0.000873	CcSEcCtD
Nifedipine—Dizziness—Carmustine—lymphatic system cancer	0.000216	0.000865	CcSEcCtD
Nifedipine—Haemoglobin—Methotrexate—lymphatic system cancer	0.000214	0.000858	CcSEcCtD
Nifedipine—Diarrhoea—Vincristine—lymphatic system cancer	0.000213	0.000855	CcSEcCtD
Nifedipine—Haemorrhage—Methotrexate—lymphatic system cancer	0.000213	0.000853	CcSEcCtD
Nifedipine—Hepatitis—Methotrexate—lymphatic system cancer	0.000213	0.000853	CcSEcCtD
Nifedipine—Pharyngitis—Methotrexate—lymphatic system cancer	0.000211	0.000847	CcSEcCtD
Nifedipine—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.00021	0.000843	CcSEcCtD
Nifedipine—Urethral disorder—Methotrexate—lymphatic system cancer	0.000209	0.000836	CcSEcCtD
Nifedipine—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000208	0.000832	CcSEcCtD
Nifedipine—Vomiting—Carmustine—lymphatic system cancer	0.000208	0.000832	CcSEcCtD
Nifedipine—Dizziness—Vincristine—lymphatic system cancer	0.000206	0.000826	CcSEcCtD
Nifedipine—Rash—Carmustine—lymphatic system cancer	0.000206	0.000825	CcSEcCtD
Nifedipine—Dermatitis—Carmustine—lymphatic system cancer	0.000206	0.000824	CcSEcCtD
Nifedipine—Visual impairment—Methotrexate—lymphatic system cancer	0.000205	0.000822	CcSEcCtD
Nifedipine—Headache—Carmustine—lymphatic system cancer	0.000205	0.00082	CcSEcCtD
Nifedipine—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000201	0.000807	CcSEcCtD
Nifedipine—Eye disorder—Methotrexate—lymphatic system cancer	0.000199	0.000797	CcSEcCtD
Nifedipine—Tinnitus—Methotrexate—lymphatic system cancer	0.000199	0.000795	CcSEcCtD
Nifedipine—Vomiting—Vincristine—lymphatic system cancer	0.000198	0.000794	CcSEcCtD
Nifedipine—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000198	0.000792	CcSEcCtD
Nifedipine—Rash—Vincristine—lymphatic system cancer	0.000197	0.000788	CcSEcCtD
Nifedipine—Dermatitis—Vincristine—lymphatic system cancer	0.000196	0.000787	CcSEcCtD
Nifedipine—Headache—Vincristine—lymphatic system cancer	0.000195	0.000783	CcSEcCtD
Nifedipine—Nausea—Carmustine—lymphatic system cancer	0.000194	0.000777	CcSEcCtD
Nifedipine—Angiopathy—Methotrexate—lymphatic system cancer	0.000193	0.000774	CcSEcCtD
Nifedipine—Vomiting—Mitoxantrone—lymphatic system cancer	0.000193	0.000774	CcSEcCtD
Nifedipine—Immune system disorder—Methotrexate—lymphatic system cancer	0.000192	0.000771	CcSEcCtD
Nifedipine—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000192	0.000769	CcSEcCtD
Nifedipine—Rash—Mitoxantrone—lymphatic system cancer	0.000191	0.000767	CcSEcCtD
Nifedipine—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000191	0.000766	CcSEcCtD
Nifedipine—Chills—Methotrexate—lymphatic system cancer	0.000191	0.000766	CcSEcCtD
Nifedipine—Headache—Mitoxantrone—lymphatic system cancer	0.00019	0.000762	CcSEcCtD
Nifedipine—Alopecia—Methotrexate—lymphatic system cancer	0.000188	0.000754	CcSEcCtD
Nifedipine—Mental disorder—Methotrexate—lymphatic system cancer	0.000187	0.000747	CcSEcCtD
Nifedipine—Malnutrition—Methotrexate—lymphatic system cancer	0.000185	0.000743	CcSEcCtD
Nifedipine—Erythema—Methotrexate—lymphatic system cancer	0.000185	0.000743	CcSEcCtD
Nifedipine—Nausea—Vincristine—lymphatic system cancer	0.000185	0.000742	CcSEcCtD
Nifedipine—Dysgeusia—Methotrexate—lymphatic system cancer	0.000182	0.000727	CcSEcCtD
Nifedipine—Nausea—Mitoxantrone—lymphatic system cancer	0.00018	0.000723	CcSEcCtD
Nifedipine—Back pain—Methotrexate—lymphatic system cancer	0.000179	0.000718	CcSEcCtD
Nifedipine—Vision blurred—Methotrexate—lymphatic system cancer	0.000175	0.0007	CcSEcCtD
Nifedipine—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000172	0.000689	CcSEcCtD
Nifedipine—Anaemia—Methotrexate—lymphatic system cancer	0.000171	0.000686	CcSEcCtD
Nifedipine—Malaise—Methotrexate—lymphatic system cancer	0.000167	0.00067	CcSEcCtD
Nifedipine—Vertigo—Methotrexate—lymphatic system cancer	0.000167	0.000667	CcSEcCtD
Nifedipine—Leukopenia—Methotrexate—lymphatic system cancer	0.000166	0.000665	CcSEcCtD
Nifedipine—Cough—Methotrexate—lymphatic system cancer	0.000162	0.000648	CcSEcCtD
Nifedipine—Myalgia—Methotrexate—lymphatic system cancer	0.000158	0.000632	CcSEcCtD
Nifedipine—Chest pain—Methotrexate—lymphatic system cancer	0.000158	0.000632	CcSEcCtD
Nifedipine—Arthralgia—Methotrexate—lymphatic system cancer	0.000158	0.000632	CcSEcCtD
Nifedipine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000157	0.000628	CcSEcCtD
Nifedipine—Discomfort—Methotrexate—lymphatic system cancer	0.000156	0.000625	CcSEcCtD
Nifedipine—Confusional state—Methotrexate—lymphatic system cancer	0.000153	0.000611	CcSEcCtD
Nifedipine—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000151	0.000606	CcSEcCtD
Nifedipine—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000148	0.000594	CcSEcCtD
Nifedipine—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000148	0.000593	CcSEcCtD
Nifedipine—Skin disorder—Methotrexate—lymphatic system cancer	0.000147	0.000589	CcSEcCtD
Nifedipine—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000146	0.000586	CcSEcCtD
Nifedipine—Anorexia—Methotrexate—lymphatic system cancer	0.000144	0.000578	CcSEcCtD
Nifedipine—Hypotension—Methotrexate—lymphatic system cancer	0.000141	0.000566	CcSEcCtD
Nifedipine—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000138	0.000552	CcSEcCtD
Nifedipine—Insomnia—Methotrexate—lymphatic system cancer	0.000137	0.000548	CcSEcCtD
Nifedipine—Paraesthesia—Methotrexate—lymphatic system cancer	0.000136	0.000544	CcSEcCtD
Nifedipine—Dyspnoea—Methotrexate—lymphatic system cancer	0.000135	0.00054	CcSEcCtD
Nifedipine—Somnolence—Methotrexate—lymphatic system cancer	0.000135	0.000539	CcSEcCtD
Nifedipine—Dyspepsia—Methotrexate—lymphatic system cancer	0.000133	0.000534	CcSEcCtD
Nifedipine—Decreased appetite—Methotrexate—lymphatic system cancer	0.000132	0.000527	CcSEcCtD
Nifedipine—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000131	0.000523	CcSEcCtD
Nifedipine—Fatigue—Methotrexate—lymphatic system cancer	0.00013	0.000523	CcSEcCtD
Nifedipine—Pain—Methotrexate—lymphatic system cancer	0.000129	0.000518	CcSEcCtD
Nifedipine—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000125	0.0005	CcSEcCtD
Nifedipine—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000124	0.000496	CcSEcCtD
Nifedipine—Urticaria—Methotrexate—lymphatic system cancer	0.00012	0.000482	CcSEcCtD
Nifedipine—Abdominal pain—Methotrexate—lymphatic system cancer	0.00012	0.000479	CcSEcCtD
Nifedipine—Body temperature increased—Methotrexate—lymphatic system cancer	0.00012	0.000479	CcSEcCtD
Nifedipine—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000111	0.000447	CcSEcCtD
Nifedipine—Asthenia—Methotrexate—lymphatic system cancer	0.000109	0.000435	CcSEcCtD
Nifedipine—Pruritus—Methotrexate—lymphatic system cancer	0.000107	0.000429	CcSEcCtD
Nifedipine—Diarrhoea—Methotrexate—lymphatic system cancer	0.000104	0.000415	CcSEcCtD
Nifedipine—Dizziness—Methotrexate—lymphatic system cancer	0.0001	0.000401	CcSEcCtD
Nifedipine—Vomiting—Methotrexate—lymphatic system cancer	9.62e-05	0.000385	CcSEcCtD
Nifedipine—Rash—Methotrexate—lymphatic system cancer	9.54e-05	0.000382	CcSEcCtD
Nifedipine—Dermatitis—Methotrexate—lymphatic system cancer	9.53e-05	0.000382	CcSEcCtD
Nifedipine—Headache—Methotrexate—lymphatic system cancer	9.48e-05	0.00038	CcSEcCtD
Nifedipine—Nausea—Methotrexate—lymphatic system cancer	8.99e-05	0.00036	CcSEcCtD
